Precipio Announces Q3-2024 Shareholder Update Call
Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, announces its Q3-2024 shareholder update conference call scheduled for November 18, 2024, at 5:00 PM EST. The call will discuss the company's Q3-2024 10-Q filing and provide financial highlights and analysis of core businesses. Shareholders can access the call via phone (844-695-5519 for domestic, 1-412-902-6760 for international) or pre-register online. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available on Precipio's website approximately 24 hours after the call.
Precipio (NASDAQ: PRPO), un'azienda specializzata nella diagnostica oncologica, annuncia la sua call di aggiornamento per gli azionisti del terzo trimestre 2024, programmata per il 18 novembre 2024, alle 17:00 EST. Durante la call verrà discusso il deposito 10-Q del terzo trimestre 2024 dell'azienda e saranno forniti evidenzi finanziari e analisi delle attività principali. Gli azionisti possono accedere alla call telefonicamente (844-695-5519 per il mercato domestico, 1-412-902-6760 per quello internazionale) o registrarsi online in anticipo. Le domande possono essere inviate in anticipo via email a investors@precipiodx.com. Una registrazione sarà disponibile sul sito web di Precipio circa 24 ore dopo la chiamata.
Precipio (NASDAQ: PRPO), una empresa especializada en diagnósticos de cáncer, anuncia su conferencia de actualización para accionistas del tercer trimestre de 2024, programada para el 18 de noviembre de 2024, a las 5:00 PM EST. La llamada discutirá la presentación 10-Q de la compañía para el tercer trimestre de 2024 y proporcionará aspectos financieros y un análisis de las actividades centrales. Los accionistas pueden acceder a la llamada por teléfono (844-695-5519 para el mercado nacional, 1-412-902-6760 para el internacional) o preinscribirse en línea. Las preguntas se pueden enviar por adelantado por correo electrónico a investors@precipiodx.com. Una grabación estará disponible en el sitio web de Precipio aproximadamente 24 horas después de la llamada.
Precipio (NASDAQ: PRPO), 전문 암 진단 회사가 2024년 11월 18일 동부 표준시 기준 오후 5시로 예정된 2024년 3분기 주주 업데이트 컨퍼런스 콜을 발표합니다. 이번 콜에서는 회사의 2024년 3분기 10-Q 제출 사항에 대해 논의하고 핵심 비즈니스의 재무 하이라이트 및 분석을 제공합니다. 주주들은 전화(국내용 844-695-5519, 국제용 1-412-902-6760)를 통해 콜에 접속하거나 온라인으로 사전 등록할 수 있습니다. 질문은 미리 이메일로 investors@precipiodx.com으로 보내실 수 있습니다. 콜 종료 후 약 24시간 이내에 Precipio의 웹사이트에서 재생할 수 있습니다.
Precipio (NASDAQ: PRPO), une entreprise spécialisée dans le diagnostic du cancer, annonce sa conférence d'actualisation pour les actionnaires du troisième trimestre 2024, prévue pour le 18 novembre 2024 à 17h00 EST. L'appel discutera du dépôt 10-Q de l'entreprise pour le troisième trimestre 2024 et fournira des points financiers clés ainsi qu'une analyse des activités principales. Les actionnaires peuvent accéder à l'appel par téléphone (844-695-5519 pour le national, 1-412-902-6760 pour l'international) ou se préinscrire en ligne. Les questions peuvent être envoyées à l'avance par e-mail à investors@precipiodx.com. Un replay sera disponible sur le site de Precipio environ 24 heures après l'appel.
Precipio (NASDAQ: PRPO), ein Unternehmen, das sich auf Krebsdiagnostik spezialisiert hat, kündigt seinen Aktionärs-Update-Call für das dritte Quartal 2024 an, der für den 18. November 2024 um 17:00 Uhr EST geplant ist. In diesem Call werden die 10-Q-Einreichung des Unternehmens für das dritte Quartal 2024 besprochen sowie finanzielle Höhepunkte und Analysen der Kernaktivitäten präsentiert. Aktionäre können über Telefon (844-695-5519 für nationale Anrufe, 1-412-902-6760 für internationale Anrufe) zugreifen oder sich online im Voraus registrieren. Fragen können im Voraus per E-Mail an investors@precipiodx.com eingereicht werden. Eine Aufzeichnung wird etwa 24 Stunden nach dem Call auf der Website von Precipio verfügbar sein.
- None.
- None.
Conference Call to be held on November 18, 2024, at 5:00 PM EST
NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET. The call will provide commentary on Precipio's Q3-2024 10-Q filed today, including financial highlights and analysis of the company's core businesses.
The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10194411/fdf400d750 and will receive a calendar invite and a direct dial-in number, bypassing the operator.
Listeners interested in submitting questions in advance should email their questions to investors@precipiodx.com and management will do its best to address those questions during the call.
A replay of the call will be available approximately 24 hours after the call and may be accessed via the Investors page on Precipio's website, https://www.precipiodx.com/investors/.
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis. For more information, please visit www.precipiodx.com.
Please follow us on LinkedIn, Twitter @PrecipioDx and on Facebook.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing.
Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
FAQ
When is Precipio (PRPO) hosting its Q3 2024 earnings call?
How can investors join Precipio's (PRPO) Q3 2024 conference call?